24 completed, 5 unknown, 1 active not recruiting. 30 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 30 | Completed 24, Unknown 5, Active not recruiting 1 |
Follow Heartburn: new trials by email Literature Review of Heartburn trials Research Report on Heartburn
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Primary carE PPi dEprescRibing Trial de-prescription of PPI via intermittent scheme, de-prescription of PPI via on-demand scheme, Alginate - Heartburn, Dyspepsia | Phase 4 | Active not recruiting | Universitaire Ziekenhuizen KU Leuven | 724 | 2023-05-12 | 2025-01-31 |
| Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease Zinc-l-carnosine, Placebo - Gastroesophageal Reflux Disease | Phase 4 | Unknown | Fondazione IRCCS Policlinico San Matteo di Pavia | 80 | 2018-11-22 | 2019-02-26 |
| Folic Acid in Pediatric Inflammatory Bowel Disease Folic Acid - Inflammatory Bowel Diseases | Phase 4 | Unknown | Le Bonheur Children's Hospital | 100 | 2018-09-11 | 2019-03-01 |
| Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment Esomeprazole 20 mg, Placebo - Heartburn | Phase 4 | Completed | Pfizer | 55 | 2016-01-01 | 2017-04-19 |
| The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease Omeprazole, LINX Reflux Management System - GERD Gastroesophageal Reflux Disease | Phase 4 | Completed | Torax Medical Incorporated | 152 | 2015-06-01 | 2019-01-07 |
| Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances sodium alginate, esomeprazole - Gastroesophageal Reflux Disease, Heartburn | Phase 4 | Unknown | Chang Gung Memorial Hospital | 340 | 2014-11-01 | 2014-11-19 |
| Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy Anesthetics, Local, Sodium Chloride 0.9% - Dyspepsia, Hematemesis | Phase 4 | Unknown | Helsinki University Central Hospital | 120 | 2014-10-01 | 2019-05-06 |
| Symptom Control Satisfaction With Proton Pump Inhibitor Regimen Optimal Dosing of Omeprazole - Heartburn | Phase 4 | Completed | MetroHealth Medical Center | 64 | 2014-08-01 | 2022-10-25 |
| Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity omeprazole+domperidone SR, omeprazole - GERD | Phase 4 | Unknown | Belarusian Medical Academy of Post-Graduate Education | 60 | 2013-12-01 | 2014-05-16 |
| Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD Mucofalk - Gastroesophageal Reflux Disease | Phase 4 | Completed | Russian Academy of Medical Sciences | 36 | 2012-04-01 | 2019-08-13 |
| Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036) Omeprazole 20 mg + Sodium Bicarbonate 1100 mg, Omeprazole 20 mg - Heartburn | Phase 4 | Completed | Bayer | 48 | 2012-01-01 | 2015-03-11 |
| To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole esomeprazole 20 mg - Gastroesophageal Reflux Disease, GERD | Phase 4 | Completed | AstraZeneca | 107 | 2011-08-01 | 2013-02-21 |
| To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole esomeprazole 40 mg - Heartburn | Phase 4 | Completed | AstraZeneca | 101 | 2010-11-01 | 2012-10-31 |
| An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease Alglucosidase Alfa, Methotrexate, Rituximab - Pompe Disease, Glycogen Storage Disease Type II | Phase 4 | Completed | Genzyme, a Sanofi Company | 4 | 2009-10-01 | 2014-05-13 |
| A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Esomeprazole 40 mg, Physical Exam, Quality of Life Questionnaires - Gastroesophageal Reflux Disease | Phase 4 | Completed | AstraZeneca | 314 | 2007-11-01 | 2012-10-10 |
| Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Immediate-release omeprazole, Delayed-release omeprazole - Gastroparesis, Gastroesophageal Reflux Disease | Phase 4 | Completed | University of Louisville | 12 | 2007-06-01 | 2017-07-28 |
| A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Esomeprazole, Rabeprazole - Gastro-oesophageal Reflux | Phase 4 | Completed | Janssen-Cilag Pty Ltd | 1392 | 2006-11-01 | 2014-04-21 |
| Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg - Gastroesophageal Reflux Disease | Phase 4 | Completed | AstraZeneca | 90 | 2006-10-01 | 2009-03-11 |
| PPI Sequencing Study Esomeprazole, Physical exam, Pregnancy test if applicable - Gastro-Oesophageal Reflux Disease | Phase 4 | Completed | AstraZeneca | 100 | 2006-09-01 | 2009-03-11 |
| Esomeprazole and Gastric Emptying of Beer esomeprazole 20 mg - Gastroesophageal Reflux, Heartburn | Phase 4 | Completed | Heidelberg University | 16 | 2006-01-01 | 2007-05-11 |
Showing 20 of 30. Sign in to see all of them.
Gastroesophageal Reflux (18) · Abdominal Pain (2) · Dyspepsia (2) · Esophagitis (1) · Esophagitis, Peptic (1) · Gastroparesis (1) · Glycogen Storage Disease Type II (1) · Hematemesis (1) · Inflammatory Bowel Diseases (1) · Nausea (1) · Parasomnias (1)
Pathological Conditions, Signs and Symptoms (30) · Signs and Symptoms (30) · Signs and Symptoms, Digestive (30) · Digestive System Diseases (20) · Gastrointestinal Diseases (20) · Deglutition Disorders (18) · Esophageal Diseases (18) · Esophageal Motility Disorders (18) · Gastroenteritis (3) · Neurologic Manifestations (3) · Intestinal Diseases (2) · Nervous System Diseases (2) · Pain (2) · Stomach Diseases (2) · Brain Diseases (1)
Esomeprazole (16) · Lansoprazole (5) · Omeprazole (4) · Pantoprazole (3) · Rabeprazole (3) · Alginates (2) · Restraint, Physical (2) · Ambulatory Care Facilities (1) · Anesthetics, Local (1) · Famotidine (1) · Folic Acid (1) · GAA protein, human (1) · Methotrexate (1) · Pregnancy Tests (1) · Psyllium (1)
AstraZeneca (12) · Bayer (2) · Belarusian Medical Academy of Post-Graduate Education (1) · Chang Gung Memorial Hospital (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Genzyme, a Sanofi Company (1) · Heidelberg University (1) · Helsinki University Central Hospital (1) · Janssen Cilag Pharmaceutica S.A.C.I., Greece (1) · Janssen-Cilag Pty Ltd (1) · Le Bonheur Children's Hospital (1) · MetroHealth Medical Center (1) · Pfizer (1) · PriCara, Unit of Ortho-McNeil, Inc. (1) · Russian Academy of Medical Sciences (1)
United States (8) · Germany (2) · Puerto Rico (2) · Argentina (1) · Australia (1) · Belarus (1) · Belgium (1) · Chile (1) · China (1) · Colombia (1) · Finland (1) · Italy (1) · Netherlands (1) · Russia (1) · Taiwan (1)
Paula Fernstrom (5) · Andreas Franke, MD (1) · Cheng-Tang Chiu, M.D. (1) · John M Wo, MD (1) · Kathryn Collison (1) · M. Michael Wolfe, MD (1) · Makiko Abe (1) · Marta Illueca, MD (1) · Masataka Date (1) · Masataka Date, MD, PhD (1)
PMID 18721738, PMID 19116333, PMID 19210493, PMID 19925497, PMID 20132153, PMID 20456300, PMID 21317257, PMID 24063425, PMID 24328943, PMID 24494987, PMID 25478944, PMID 26063325, PMID 27104192, PMID 28107279, PMID 28406440, PMID 28607547, PMID 30031018, PMID 30094626, PMID 30255418, PMID 31518717, PMID 32467089, PMID 41949151, PMID 41997699